PLANTATION, Fla.--(BUSINESS WIRE)--Goodwin Biotechnology Inc. (GBI) disclosed today that following its recent formation, AREVA Med LLC has decided to extend its collaboration with GBI toward the development of AREVA Med’s lead-212 (212Pb) initiative to treat cancer. The operation previously engaged with AREVA will continue with AREVA Med and will result in the manufacture of a new conjugated drug that will be radiolabeled by the NCI. AREVA Med will benefit from the vast expertise in the nuclear industry from its parent company that allowed for the production of this radioisotope previously considered a scarce resource.
